Evans Christopher H, Chevalier Xavier, Wehling Peter
Rehabilitation Medicine Research Center, Mayo Clinic, 200, First Street Southwest, Rochester, MN 55905, USA.
Department of Rheumatology, Hopital Henri Mondor, UPEC Paris XII University, Bd De latter de Tassigny, Creteil 94010, France.
Phys Med Rehabil Clin N Am. 2016 Nov;27(4):893-908. doi: 10.1016/j.pmr.2016.06.003.
Autologous conditioned serum was developed in the mid 1990s as an expeditious, practical, and relatively inexpensive means of generating the interleukin-1 receptor antagonist, a naturally occurring inhibitor of the cytokine interleukin-1. The latter is thought to be an important mediator of inflammation, pain, and tissue destruction in musculoskeletal conditions. ACS has been widely and successfully used in the local treatment of human and equine osteoarthritis and radicular compression; it has also shown promise in treating tendinopathies, muscle injuries, and tunnel widening after reconstruction of the anterior cruciate ligament. Experience suggests that autologous conditioned serum is safe and effective.
自体条件血清于20世纪90年代中期研发出来，是一种快速、实用且相对廉价的生成白细胞介素-1受体拮抗剂的方法，白细胞介素-1受体拮抗剂是细胞因子白细胞介素-1的一种天然抑制剂。后者被认为是肌肉骨骼疾病中炎症、疼痛和组织破坏的重要介质。自体条件血清已广泛且成功地用于人和马的骨关节炎及神经根受压的局部治疗；它在治疗肌腱病、肌肉损伤以及前交叉韧带重建术后隧道增宽方面也显示出前景。经验表明，自体条件血清安全有效。
